Instituto Universitario de Oftalmobiología Aplicada

Sesión III.
Moderador : D. Jose Alberto San Román
Gestión de la investigación en un centro de Investigación Mixto
D. José Carlos Pastor – Instituto Universitario de Oftalmología Aplicada
Instituto Universitario de
Oftalmobiología Aplicada (IOBA)
[Eye Institute]
University of Valladolid
Valladolid
Spain
Historia resumida del IOBA
y Propuesto a la Junta de Gobierno de la Uva en 1989
y Instituto de la Universidad en Noviembre de 1989
y Dos divisiones:
Oftalmología 17 investigadores clínicos
y Farmacología 7 investigadores clínicos
y 2 técnicos de laboratorio, 2 PAS
y Presupuesto 12.000 €
y
y Instituto LRU en Diciembre de 1994
y 1ª Evaluación de la Junta de Castilla y León 1999
y 2 Evaluación de la Junta 2005
y Traslado edificio Campus Miguel Delibes 2007 y
20008
IOBA 2009
y Approved by the Spanish Government in December
1994
y Located at our own building since 2007 (FEDER
funded: 4,5 M€): 4.000 m2
y Move ended November 2008
y Self-financed
y Budget 2009: 4 M € (2,6 M€ clinical activities, 1,4 M€
research)
y Around 100 members (60 contracts): three areas:
clinical, research and teaching activities
IOBA 2009
y Clinical area:
y 14 ophthalmologists (comprehensive and sub-
specialized Ophthalmology)
y 18.000 out-patients clinic attendances in 2008
y 4,000 new patients
y
y
y
41% private
24% insurance companies
35% National Health Service
y 1,400 day surgeries
y Quality certified since 2006 (ISO 9000)
Research structure
y 4 major research groups
y
y
y
y
y
5 major horizontal programs
y
y
y
y
y
y
Ocular Surface
Refractive Surgery and Quality of Vision
Retina
Glaucoma
Dry Eye Disease Program (sponsored by Allergan)
Cell Therapy ( Advanced Therapies) in Ophthalmology
Applied Genetics in Ophthalmology
Low Vision and Rehabilitation
Telemedicine
Common labs and units
y
y
y
y
y
Cell Culture lab
Immunology lab
Ocular Pathology lab
Biostatistics Unit
Clinical Trial Unit
9 basic senior investigators
12 clinical investigators
10 basic predoctoral
investigators
10 students PhD program
7 technicians
Ocular Pathology lab
y Clinical diagnosis and research support
y Prof. Forteza, MD, PhD academic
director
y Prof. Cuevas, MD, PhD coordinator of
teaching activities
y Denise Hileeto, MD (Residency in
Pathology at Yale University)
y Two technicians
y More than 7,000 ocular samples (2009)
Ocular Pathology lab: projects in
2010
Adquisition of a digital microscope ASIC III
Integration in a Telepathology Network
Proposed as part of an Ophthalmic BIOBANK
Clinical Trials Unit
y Created in 2001: 12 clinical trials since then
y Member of EVI.CT.SE since 2006
y Fully certified in 2008
coordination of “independent”
clinical trials supported by Carlos III
Institute
y Triamcinolone acetonide for DME (already
finished 2009)
y Avastin for Myopic choroidal
neovascularization (recruitment period closed
2009)
y Avastin for macular edema after reinal vein
occlusion (EVOBER) (starting in 2009)
Teaching activities (post-graduate)
y Masterships recognized by EU:
y
Interuniversity Vision Research Mastership
(already verified by ANECA: U Complutense
Madrid, Santiago, Murcia, Coimbra, CSIC)
y Retina
y Ocular Surface and Immunology
y Oculoplastic surgery
y ANECA verified in 2009
y Masterships of the University:
y Glaucoma
y Clinical Optometry
y Visual Rehabilitation (proposed as an official Master in 2009)
y Ophthalmic Nursing
y Continous Education Program in Ophthalmology
Angola´s project
Since 1995
y Over 1,6 M€
y 44 people travelling
y Biopsies processed and informed at
Valladolid
y Residency in Ophthalmology
y Mastership in Ophthalmic Nursing
y 2009-2011
y State Grant to Angola’s Government
y Prophylaxis of neonatal conjunctivitis
IOBA is a member of the most outstanding
biomedical research structures created by
Spanish Government:
Associated Unit CSIC, CIBER-BBN,
Thematic Network 0062, TerCel Network,
Network Center for Regenerative Medicine
and Cell Therapy of Castilla and Leon
International cooperations (official
agreements)
y McGill University (Montreal, Canada), Baylor
College (Houston, USA), Texas University at
Dallas (USA) UCL (London, UK), Roma
Campus Biomédico (Italia), University of
Hälle (Germany), IBILI (Coimbra, Portugal),
Moorfields Eye Hospital (London, UK),
University of Porto (Portugal), Rotterdam Eye
Hospital (Netherlands), Vienna Eye Hospital
(Austria), University of Lisbon (Portugal),
Instituto Gama Pinto (Lisbon, Portugal)
International cooperations (in
discussion)
y Heilderbeg (Germany)
y Liverpool and Bristol (UK)
y Institute de la Vision (Paris, France)
y Universidade Federal de Sao Paulo (Brasil)
y Beijing Eye Institute (China)
Coordination of clinical networks
y Risk factors for PVR development (Retina 1)
y Efficacy and safety of intravitreal TA for DME
y
y
y
y
y
(Retina 3)
Genetic approach to PVR (Retina 4)
Avastin ® for CNV in pathologic myopia
(Macula 2)
Autologous limbal transplantation vs
conjunctival rotation for pterygium
Autologous expanded limbal stem cells
transplantation
Graft vs host disease (ocular manifestations)
RETINA 1: multicentric study
•Instituto Oftalmológico de Alicante. Alicante
•Clínica Barraquer. Barcelona
•Hospital Universitario Vall d´Hebró. Barcelona
•Hospital Reina Sofía. Córdoba
•Hospital San Millán. Logroño
•Hospital Ramón y Cajal. Madrid
•Hospital Donostia. San Sebastián
•Grupo de Retina IOBA, Valladolid
•Hospital Pío del Río Hortega, Valladolid
•Hospital Universitario de Valladolid
Red Temática de Investigación
Cooperativa Sanitaria 03/13
•Hospital General Universitario de Valencia
•Hospital Universitario de Canarias
•Fundación Oftalmológica del Mediterraneo
•Hospital Universitario de Salamanca
•Hospital General Yagüe de Burgos
•Hospital Universitario de Coimbra. Coimbra. PORTUGAL
•Hospital de San Joao. Oporto. PORTUGAL
2 papers
already
in BJO
Data: February-2005
March 2008:
1,339published
RD
RETINA 4 (Red Temática 03/13)
450 blood samples:
Multicentric study
312 Primary RD without PVR 3 months follow up
138 PVR after primary RD
Centro
Total/centro
DR
VRP
Hospital Clínico Universitario
60
28
32
Hospital del Río Hortega
17
10
7
Hospital Universitario de Donostia
42
35
7
Hospital Universitario Reina Sofía
14
9
5
Hospital Vall d'Hebrón
95
75
20
Instituto Barraquer
43
35
8
129
98
31
IOBA
50
22
28
Total
450
312
138
Instituto Oftalmológico Vissum
Retina 4
y
y
y
y
TNF α
TNFR-2
SMAD7
PIK·CG
y
y
Patent pending 200702532
Procedure for dtecting high risk of
developing PVR based on SNPs
Retina 4
y Duplication and validation
800 samples
y Retina 1 project centers
y Moorfields Eye Hospital
y Rotterdam Eye Hospital
y Vienna Eye Hospital
y
October 2009 460 samples
Preliminary data published in IOVS
IOBA’s applied research achievements
y Spin-off: Vision I+D
y Controlled enviromental chamber
y Patents
y Registries
y Transference of technologies
y Contracts with industries
C. E. Chamber
y Temperature, humidity and pressure controlled
y Possibilities: clinical studies in normal volunteers and
patients with ocular inflammatory processes
y Specific diagnostic test under controlled conditions
y Should be operative by November 2009
Pressure 400 mbar
Temperature 15 to 30 ºC
Humidity 5%-80%
17.000 kg of steel
Patents
10 in 12 years
(3 in process)
2 registries
1 transference of technology
IOBA - Ciber BBN
Ciber BBN prototype. Rigid gas permeable contact lens
Pub. No.: P200801822
Pub Date. Jun. 6, 2008
PATENT
Material: Biocompatible polymer
Next year’s tasks:
Soft contact lens of material HEMA
or HSi
Sensor could be polimerized with
the contact lens material
Patent pending 2008
Contracts with industries:
Allergan (2004-2011) $1, 8 M Ocular inflammation
y Alcon (2006-2009) polymers as drug release
systems
y Thea- Transphyto
y AJL-Ophtalmics
Chairs funded by enterprises:
y Alcon
y Esteve
y Novartis
y Topcon
Agreements with:
y Lilly, Essilor, Zeiss, Bioftalmik, Cellerix
y
Ceguera de origen corneal: Reconstrucción de la superficie ocular
mediante terapia celular e ingeniería de tejidos
Ensayo clínico en pacientes con Síndrome de Insuficiencia límbica
Ceguera de origen corneal: Reconstrucción de la superficie ocular
mediante terapia celular e ingeniería de tejidos
Ensayo clínico en pacientes con Síndrome de Insuficiencia límbica
UPC
IBGM, UVa
New project, starting 2009
y Development of customized intraocular lenses
for pets
y Leon Veterinarian School
y AJL-Ophthalmics (Vitoria, Spain)
Future
y Foundation
y BioBank ocular diseases oriented
y Expand European relations
y Creation of 2 new spin-off
E-Diagnostics
y Critical Health
y
Eye care products market $ 14,5 bn
y Ophthalmic Pharmaceuticals market
y $ 10 bn in 2007
y 2009-2023 will grow steadily driven by
increasing prevalence of ophthalmic disorders
amongst an expanding population of older
people
y Contact Lens market
y 1,2 bn € in 2008
Proposal: creation of a biomedical
translational research structure based
on eye and vision: consortium?
y Universities
Valladolid
y Salamanca
y Leon
y Carlos III
y CSIC (Optics and
Polymers Institutes)
Technological centers:
y INASMET
y CIDETEC
y
Companies:
•AJL Ophthalmics
•Progenika
•Bioftalmik
•Vision I+D
Pipe-line
y Ocular surface research
y
Dry eye , allergy and inflammation
y Diagnostic tests
y Therapeutical targets
y
Cell therapy
y Protocols
y Patents
y Technological development
Filters and aids for low vision
y Ocular lens for estimating intraocular pressure
y Automatic image analysis
y
y Retina
y
Advanced therapies